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Case presentation
The patient is a right-handed White woman with relapsing-remitting MS diagnosed subsequent
to left acute optic neuritis (AON). She described a previous transient episode of severe,
electrical, and paroxysmal facial pain consistent with trigeminal neuralgia. Initial MRI demonstrated supratentorial hyperintensities consistent with plaques of inﬂammatory demyelination. CSF analysis demonstrated oligoclonal bands that were not present in blood
samples.
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The patient’s medical history was signiﬁcant for multiple evanescent white dot syndrome
(MEWDS) in her left eye and a left hemianopic defect at baseline. MEWDS, typically aﬀects
young women, is commonly unilateral and secondary to viral illness. Transient white dots are
observed at the level of the retinal pigmented epithelium and result in painless, sudden
monocular visual ﬁeld loss localized to the central ﬁeld.
The patient was adherent with azathioprine as an MS disease-modifying therapy (DMT), and
she remained neurologically stable for 8 years from her initial episode of AON until she
developed a second episode of painful left AON. Believed to represent breakthrough activity in
the patient’s MS, she was transitioned to a combination therapy regimen comprising weekly IM
interferon β-1a and mycophenolate mofetil (ﬁgure 1).
She remained stable for an additional 12 years until she developed a third episode of painful left
AON. Further investigations, including cell-based assay assessments for both aquaporin 4 and
antimyelin oligodendrocyte glycoprotein antibodies, were unrevealing. The patient’s DMT
regimen at this point was changed to ﬁngolimod, with a clinical course complicated by herpes
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Figure 1 Chronological heat map

In this figure, we detail the condition of the patient over time. The longitudinal axis (left to right) depicts the condition of disease, where the smaller amplitude
and lighter color indicates greater stability of MS. Alternately, the expanded amplitude of the colored heat map (above and below the horizontal linear axis
over time) designates increased disease activity (whether on a clinical or paraclinical basis) or complications of the treatment of disease (e.g., PML). Four other
fields of information are added either above or below the heat map and include information about treatments, diagnoses, commentaries adding contextual
perspectives, and results from specific test assessments; including representative MRI images from each most relevant period of clinical decision-making,
Humphrey automated visual field analysis and pure tone audiometry hearing thresholds over time and in response to therapeutic interventions. Each field is
consistently color coded throughout as defined in the figure legend. IVIG = IV immunoglobulin; JCV = John Cunningham virus; MEWDS = multiple evanescent
white dot syndrome; PML = progressive multifocal leukoencephalopathy.

simplex 1 meningitis 3 months after initiation of this new
therapy and recovered after a course of IV acyclovir.
Fingolimod was continued for 12 months until she developed the abrupt onset of profound hearing loss on the
left. Investigations conﬁrmed central hearing loss, with an
approximately 90 dB threshold on the left (ﬁgure 1). MRI
failed to exhibit any new or active lesions, and MR angiographies of the carotid and vertebrobasilar circulations
were normal.
In the absence of any improvement in her hearing after the
administration of both IV and oral corticosteroids, we intensiﬁed her therapy with punctuated cycles of plasma exchange (PLEX). These treatments resulted in an
improvement of 10–20 dB of hearing threshold after each
of 3 cycles of plasma exchange (each consisting of 5 full
volume exchanges), rescuing about 50 of the 90 dB
threshold derangement that characterized her left-sided
hearing loss (ﬁgure 1).
Given concern of auditory complications as a drug side
eﬀect of ﬁngolimod,1–4 it was discontinued. The patient
was started on weekly etanercept, an antitumor necrosis
factor (TNF) agent with audiologic protective eﬀects.4
Speciﬁcally, TNF modulatory medications are beneﬁcial in
treating severe neurosensory hearing loss,4 autoimmune
labyrinthitis, noise-related hearing loss, and in promoting
2

recovery after facial nerve injury.5 Alternately, TNF
blockers have been associated with the CNS and peripheral
nervous system demyelinating syndromes.6
In lieu of this risk that etanercept might precipitate an MS
exacerbation, we further intensiﬁed the patient’s MS DMT
with natalizumab. Given the patient’s positive John Cunningham (JC) virus immunoglobulin G status, we decided
to administer every 8-week extended interval dosing (EID)
of natalizumab, given that evidence was emerging to
demonstrate that such a longer latency between treatments
was not associated with a compromise in clinical or paraclinical measures of MS disease activity7 while simultaneously mitigating the risk of progressive multifocal
leukoencephalopathy (PML), when compared with standard interval dosing of every 4-week treatments.8,9 The
ﬁrst infusion was strategically administered 1 week before
inception of etanercept treatment.
Ten months after the inception of EID of natalizumab, etanercept, and cycles of PLEX, our patient noticed diminished
coordination and volitional control when attempting to use
her right arm, and 2 months henceforth, she developed dysarthric speech and intermittent falls.
Urgent examination demonstrated downbeat nystagmus and
saccadic dysmetria. Eccentric gaze holding to the right
revealed gaze-evoked nystagmus, consistent with a “leaky”
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neural integrator (implicating cerebellar ﬂocculus dysfunction). Furthermore, we observed low-gain smooth pursuit eye
movements to the right and a reduced vestibulo-ocular reﬂex
suppression (VORS) on attempted head/eye combined
motion to the right in conjunction with a course tremor in the
right arm.
Brain MRI revealed many “punctate” enhancing lesions
spanning all 3 levels of the brainstem, albeit most signiﬁcantly
aﬀected was the right pons and the right cerebellum (ﬁgure 2).
Differential diagnosis
The constellation of punctate enhancements was reminiscent
of chronic lymphocytic inﬂammation with pontine perivascular enhancement responsive to steroids (CLIPPERS).
We failed to detect the 68kd inner ear antigen antibody (also
known as heat shock protein 70); a potential etiology of inner
ear autoimmune disease. Given the administration of intensive immune therapies, a diagnosis of PML was most likely
and was conﬁrmed when CSF analysis revealed the presence
of 2180 JC virions/mL (ﬁgure 1).10–12
Final diagnosis
The patient was diagnosed with PML, and treatment was
aimed at ﬁrst promoting an attenuated immune reconstitution
to avoid CNS damage from the immune reconstitution inﬂammatory syndrome (IRIS), then followed by the initiation
of a new MS DMT.

Natalizumab was discontinued and 3 courses of PLEX (at 1
full volume daily for a total of 3 days) were performed to
remove natalizumab. To reduce the risk of CNS IRIS, we
initiated 12 weeks of IV methylprednisolone dosed 1 g per
week, then followed by every other week infusions of methylprednisolone for 6 doses, and then monthly for 3 ﬁnal
doses.13
After PLEX and corticosteroids, the patient demonstrated
improvement of her saccadic dysmetria, right arm coarse
tremor, VOR cancellation, down beating nystagmus, and
dysarthria. Notwithstanding improvements she exhibited
substantial neurologic deﬁcits including dependency on a
cane and walker for ambulation. Seven months after corticosteroid therapy, JC virus was undetectable in both blood
and CSF (ﬁgure 1).
In June 2016, it was decided to commence MS DMT with
alemtuzumab, an anti-CD52 monoclonal antibody. After
cellular depletion, bone marrow mobilization of
B lymphocytes in large numbers occurs producing a discordant B cell hyper-repopulation (generally within 3–6 months)
with T cells approximating baseline levels at 12–24 months.
This period of B cell hyper-repopulation includes the presence of CD20+ T cells—exhibiting a proinﬂammatory phenotype, which has been hypothesized to promote B cell
antigen presentation in the absence of T cell help—a time
where B cells cannot diﬀerentiate between self and non–self-

Figure 2 Cataclysmic disease activity associated with PML is abolished with intensive immunotherapy

(A) T1-weighted postgadolinium MRI images performed on April 2014. (B) T2-weighted MRI images performed on April 2014. (C) T2-FLAIR MRI images
performed on July 2019 and revealing striking resolution of the disease processes previously active from PML, and potentially with some component of IRIS.
FLAIR = fluid-attenuated inversion recovery; IRIS = immune reconstitution inflammatory syndrome; PML = progressive multifocal leukoencephalopathy.
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epitopes; and which may be mechanistically germane to the
high incidence of secondary autoimmunity associated with
alemtuzumab DMT in MS.14
A recently published report theorized that a “Whack-A-Mole”
B cell depletion strategy involving the punctuated administration of 100 mg of rituximab, temporally synchronized with
the return of B lymphocytes, may be capable of mitigating
secondary autoimmunity associated with alemtuzumab DMT
for MS by abolishing the discordant and precocious B cell
hyper-repopulation while also deleting CD20+ T cells.
Our patient received 1 course of alemtuzumab (5 consecutive
days of IV treatment). Furthermore, she was treated with the
“Whack-A-Mole” B cell depletion regimen with 100 mg of
rituximab when her CD19+ cells approximated 40%–50% of
baseline levels.14

Our case highlights the importance of recognizing side eﬀects
from common DMTs and the need for closely monitoring
patients undergoing transitions across immunotherapies. We
believe that the timely identiﬁcation of PML, followed by
prompt intervention with PLEX and employment with one of
the AIDS-PML corticosteroid IRIS-dampening regimens in
those undergoing highly active antiretroviral therapy13 were
paramount to mitigating both our patient’s morbidity and

Figure 3 Serial pattern deviation plots from Humphrey
automated perimetry reveals recovery following
intensive immunotherapy

One year after alemtuzumab therapy, our patient’s dysarthria resolved, and she recovered her ability to ambulate
independently. All of her cerebellar and brainstem signs
and symptoms disappeared. Likewise, marked improvements on her brain MRI (ﬁgure 2) and near resolution of
her left eye hemianopic ﬁeld defect was documented
(ﬁgure 3). Fifty-one months since the inception of alemtuzumab treatment, our patient exhibits “no evidence of
MS-related disease activity,” and she remains free of any
evidence of secondary autoimmunity.

Discussion
Our patient’s disease course was characterized by multiple
inﬂammatory exacerbations despite adherence to diﬀerent
treatment strategies, including long periods of combination
therapy. While on ﬁngolimod, she developed herpetic meningitis and, about a year later, left-sided neurosensory hearing
loss. A broad diagnostic series of investigations for infectious,
vascular, inﬂammatory/demyelinating, neoplastic, paraneoplastic, and autoimmune disorders failed to elucidate an explanation, other than an adverse manifestation of ﬁngolimod.
The principal objectives for the aggressive interventions
characterized in our case report, were ﬁrst aimed at achieving
remission of the disease process responsible for our patient’s
neurosensory hearing loss, followed by our attempt to promote recovery in her hearing on the left.
At the time of beginning the every 8-week dosing of natalizumab, there was already report of a cohort of patients with
MS treated with EID of natalizumab with no documented
cases of PML.8,15 Nevertheless, the previous utilization of
immune suppressive therapies in the context of etanercept
and steroid therapy—along with the coadministration of
natalizumab (even at 8-week dosing)—likely combined to
escalate the risk for the development of PML in our patient.
4

(A) Pattern deviation for automated Humphrey visual fields (HVFs) using the
30-2 test from July 1996. (B) Pattern deviation for automated HVF 30-2 from
January 2000. (C) Pattern deviation for automated HVF 30-2 from July 2016.
(D) Pattern deviation for automated HVF 30-2 from February 2020 demonstrating striking resolution of the previously protracted visual field suppression in a left homonymous hemianopic pattern.
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mortality. Furthermore, alemtuzumab therapy in conjunction
with our “Whack-A-Mole” B-cell depletion strategy14 was
used for purposes of promoting a durable remission and potentially to obviate the development of alemtuzumabassociated secondary autoimmunity.
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CORRECTION

Treating MS after surviving PML: Discrete strategies for rescue,
remission, and recovery patient 2
From the National Multiple Sclerosis Society Case Conference Proceedings
Neurol Neuroimmunol Neuroinﬂamm 2021;8:e968. doi:10.1212/NXI.0000000000000968

In the Neurology® Neuroimmunology & Neuroinﬂammation Article “Treating MS after surviving
PML: Discrete strategies for rescue, remission, and recovery patient 2: From the National
Multiple Sclerosis Society Case Conference Proceedings” by R. Cruz et al.,1 the 15th author’s
name and credentials should be listed as “Scott D. Newsome, DO.” The authors regret the
error.
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